15+ Years at Wyss Institute at Harvard University      |      10+ Years in Pharmaceutical Development Industry

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Standard treatment for tendon injuries often means injections that wear off quickly or drugs that go through your entire body, causing side effects. What if we could place a tiny "drug depot" right at the injury site that lasts for weeks? 🏥 Our team at the Wyss Institute has developed a new tough composite hydrogel that does exactly that. By harnessing the power of clay nanoparticl

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies An animation to accompany our "Modular biomaterials vaccine technology protects against multiple pathogens and septic shock" paper, where we describe the development of ciVAX (Composite Infection Vaccine), a modular, injectable biomaterial scaffold designed to provide broad-spectrum protection against lethal bacterial infections and sepsis. Full report @ https://is.gd/CzSnuk #sepsis

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Our "Modular biomaterials vaccine technology protects against multiple pathogens and septic shock" paper describes the development of ciVAX (Composite Infection Vaccine), a modular, injectable biomaterial scaffold designed to provide broad-spectrum protection against lethal bacterial infections and sepsis. Full report @ https://is.gd/CzSnuk #sepsis #vaccines #Biomaterials #medtech #

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Our recently published article entitled "Kinetics of De Novo Bone and Bone Marrow Niche Formation With Hybrid Click Cryogels", explores strategies to rebuild the bone marrow environment to improve the success of hematopoietic stem cell transplantation (HSCT). Full report @ https://is.gd/1tleYm Main Objective The study addresses the problem of damaged bone marrow niches following irr